A study of prevalence of polymorphic variants of genes of blood coagulation factors in onco-logical patients

Abstract

Aim. To study the prevalence of carriage of polymorphic allele variants of genes of blood coagulation factors in oncological patients.

Materials and Methods. 213 Patients with morphologically confirmed oncological diseases were examined. Samples of genomic DNA of peripheral blood of the patients were examined. Using polymerase chain reaction (PCR), polymorphic sites of genes of hemostatic system were studied in real time: F2 (G20210А, rs1799963), F5 (G1691A, rs6025), F7 (G10976A, rs6046), F13 (G226A, rs5985), FGB G(-455)A (rs1800790), ITGA2-α2 (C807T, rs1126643), ITGB3-b (Т1565С, rs5918), PAI-1 4G(-675)5G, rs1799889).

Results. The prevalence of carriage of alternative allele of F2 (G20210А) polymorphic locus in the studied group was 1.6%, of F5 (G1691A) – 3.5%, of F7 (G10976A) – 13.4%, of F13 (G226A) – 28.2%, of FGB G(-455)A – 24.9%, of ITGA2-α2 (C807T) – 41.5%, of ITGB3-b (Т1565С) – 15.5%, of PAI-1 4G(-675)5G – 56.6%. A statistically significant increase in the frequency of ‘risk alleles’ of F5 G1691A (р=0.0169), F13 G226A (р=0.0007), FGB G(-455)A (р<0.0001) and ITGA2-α2 C807T (р=0.0201) polymorphic loci was found in oncological patients as compared to the general population. In the same loci, except ITGA2-α2 (C807T), statistically significant differences in the frequency of alternative alleles were found in different localizations of the oncological process. In 92.0% of patients, SNR combination was determined in different components of hemostatic system.

Conclusion. Taking into account a high frequency of identification of ‘risk alleles’ in all components of hemostatic system, it is reasonable to carry out additional research to determine the necessity of addition of antiaggregants to antithrombotic therapy in oncological patients.

Keywords

polymorphic sites / genes of blood coagulation factors / thrombotic complications / oncology

References

[1] Rosendaal FR, Reitsma PH. Genetics of venous thrombosis. Journal of Thrombosis and Haemostasis. 2009;Suppl. 1:301-4. doi:10.1111/j.1538-7836.2009. 03394.x

[2] Rosendaal F.R., Reitsma P.H. Genetics of venous thrombosis // Journal of Thrombosis and Haemostasis. 2009. Suppl. 1. P. 301-304. doi:10.1111/ j.1538-7836.2009.03394.x

[3] Naess IA, Christiansen SC, Romundstad P, et al. Incidence and mortality of venous thrombosis: a population-based study. Journal of Thrombosis and Haemostasis. 2007;5(4):692-9. doi:10.1111/j.1538-7836.2007.02450.x

[4] Naess I.A., Christiansen S.C., Romundstad P., et al. Incidence and mortality of venous thrombosis: a population-based study // Journal of Thrombosis and Haemostasis. 2007. Vol. 5, №4. P. 692-699. doi:10.1111/j.1538-7836.2007.02450.x

[5] Kyrle PA, Minar E, Bialonczyk C, et al. The risk of recurrent venous thromboembolism in men and women. N Engl J Med. 2004;350(25):2558-63. doi:10.1056/NEJMoa032959

[6] Kyrle P.A., Minar E., Bialonczyk C., et al. The risk of recurrent venous thromboembolism in men and women // The New England Journal of Medicine. 2004. Vol. 350, №25. P. 2558-2563. doi:10.1056/ NEJMoa032959

[7] Vorobev AV, Makatsaria AD, Chabrov AM, et al. Pathogenesis of Trousseau’s syndrome. Journal of Obstetrics and Woman’s Diseases. 2015;64(4):85-94. (In Russ).

[8] Воробьев А.В., Макацария А.Д., Чабров А.М., и др. Cиндром Труссо: современный взгляд на проблему // Журнал акушерства и женских болезней. 2015. Т. 64, №4. С. 85-94.

[9] Falanga A, Marchetti M. Hemostatic biomarkers in cancer progression. Thrombosis Research. 2018;164 (Suppl 1):S54-S61. doi:10.1016/j.thromres.2018.01.017

[10] Falanga A., Marchetti M. Hemostatic biomarkers in cancer progression // Thrombosis Research. 2018. Vol. 164, Suppl 1. P. S54-S61. doi:10.1016/ j.thromres.2018.01.017

[11] Cronin-Fenton DP, Sondergaard F, Pedersen LA, et al. Hospitalisation for venous thromboembolism in cancer pa-tients and the general population: a population-based cohort study in Denmark, 1997-2006. British Journal of Can-cer. 2010;103(7):947-53. doi:10.1038/sj.bjc.6605883

[12] Cronin-Fenton D.P., Sondergaard F., Pedersen L.A., et al. Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997–2006 // British Journal of Cancer. 2010. Vol. 103, №7. P. 947-953. doi:10.1038/sj.bjc.6605883

[13] Chew HK, Wun T, Harvey D, et al. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Archives of Internal Medicine. 2006;166(4):458-64. doi:10.1001/ archinte.166.4.458

[14] Chew H.K., Wun T., Harvey D., et al. Incidence of venous thromboembolism and its effect on survival among pa-tients with common cancers // Archives of Internal Medicine. 2006. Vol. 166, №4. P. 458-464. doi:10.1001/archinte.166.4.458

[15] Francis CW, Kessler CM, Goldhaber SZ, et al. Treatment of venous thromboembolism in cancer patients with dalte-parin for up to 12 months: the DALTECAN study. Journal of Thrombosis and Hae-mostasis. 2015;13(6):1028-35. doi:10.1111/jth.12923

[16] Francis C.W., Kessler C.M., Goldhaber S.Z., et al. Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN study // Journal of Thrombosis and Haemostasis. 2015. Vol. 13, №6. P. 1028-1035. doi:10.1111/jth.12923

[17] Horsted F, West J, Grainge MJ. Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLoS Medicine. 2012;9 (7):e1001275. doi:10.1371/journal.pmed.1001275

[18] Horsted F., West J., Grainge M.J. Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis // PLoS Medicine. 2012. Vol. 9, №7. P. e1001275. doi:10.1371/ journal.pmed.1001275

[19] Li M, Guo Q, Hu W. Incidence, risk factors, and out comes of venous thromboembolism after oncologic surgery: A systematic review and meta-analysis. Thrombosis Research. 2019;173:48-56. doi:10.1016/j.thromres.2018.11.012

[20] Li M., Guo Q., Hu W. Incidence, risk factors, and outcomes of venous thromboembolism after oncologic surgery: A systematic review and meta-analysis // Thrombosis Research. 2019. Vol. 173. P. 48-56. doi:10.1016/j.thromres.2018.11.012

[21] Lee AY, Peterson EA. Treatment of cancer-associated thrombosis. Blood. 2013;122(14):2310-7. doi:10.1182/blood-2013-04-460162

[22] Lee A.Y., Peterson E.A. Treatment of cancer-asso-ciated thrombosis // Blood. 2013. Vol. 122, №14. P. 2310-2317. doi:10.1182/blood-2013-04-460162

[23] Timp JF, Braekkan SK, Versteeg HH, et al. Epidemiology of cancer-associated venous thrombosis. Blood. 2013;122(10):1712-23. doi:10.1182/blood-2013-04-460121

[24] Timp J.F., Braekkan S.K., Versteeg H.H., et al. Epidemiology of cancer-associated venous thrombosis // Blood. 2013. Vol. 122, №10. P. 1712-1723. doi:10.1182/blood-2013-04-460121

[25] Vossen CY, Hoffmeister M, Chang-Claude JC, et al. Clotting factor gene polymorphisms and colorectal cancer risk. Journal of Clinical Oncology. 2011;29(13):1722-7. doi:10.1200/JCO.2010.31.8873

[26] Vossen C.Y., Hoffmeister M., Chang-Claude J.C., et al. Clotting factor gene polymorphisms and colorectal cancer risk // Journal of Clinical Oncology. 2011. Vol. 29, №13. P. 1722-1727. doi:10.1200/ JCO.2010.31.8873

[27] Tinholt M, Viken MK, Dahm AE, et al. Increased coagulation activity and genetic polymorphisms in the F5, F10 and EPCR genes are associated with breast cancer: a case-control study. BMC Cancer. 2014;14:845. doi:10.1186/1471-2407-14-845

[28] Tinholt M., Viken M.K., Dahm, A.E., et al. Increased coagulation activity and genetic polymorphisms in the F5, F10 and EPCR genes are associated with breast cancer: a case-control study // BMC Cancer. 2014. Vol. 14. P. 845. doi:10.1186/ 1471-2407-14-845

[29] Blom JW, Doggen CJ, Osanto S, et al. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293(6):715-22. doi:10.1001/ jama.293.6.715

[30] Blom J.W., Doggen C.J., Osanto S., et al. Malignancies, prothrombotic mutations, and the risk of venous thrombosis // JAMA. 2005. Vol. 293, №6. P. 715-722. doi:10.1001/jama.293.6.715

[31] Vorobev AV, Chabrov AM, Savchenko AA., et al. Pathogenesis of Trousseau's syndrome. Obstetrics, Gynecology and Reproduction. 2015;9(2):99-109. (In Russ). doi:10.17749/2070-4968.2015.9.2.099-109

[32] Воробьев А.В., Чабров А.М., Савченко А.А., и др. Вопросы патогенеза синдрома Труссо // Акушерство, гине-кология и репродукция. 2015. Т. 9, №2. С. 99-109. doi:10.17749/2070-4968. 2015.9.2.099-109

[33] Smigielski EM, Sirotkin K, Ward M, et al. dbSNP: a database of single nucleotide polymorphisms. Nucleic Acids Re-search. 2000;28(1):352-5. doi:10. 1093/nar/28.1.352

[34] Smigielski E.M., Sirotkin K., Ward M., et al. dbSNP: a database of single nucleotide polymorphisms // Nucleic Acids Research. 2000. Vol. 28, №1. P. 352-355. doi:10.1093/nar/28.1.352

[35] Kit OI, Katelnitskaya OV, Guskova NK, et al. Experience with the treatment of venous thromboembolism in oncolo-gy patients with the use of dabigatran. Flebologiya. 2016;10(1):29-34. (In Russ). doi:10.17116/flebo201610129-34

[36] Кит О.И., Кательницкая О.В., Гуськова Н.К., и др. Опыт лечения венозных тромбоэмболических осложнений в онкологии дабигатраном // Флебология. 2016. Т. 10, №1. С. 29-34. doi:10. 17116/flebo201610129-34

[37] Strozenko LA, Gordeev VV, Lobanov YF, et al. Frequency of carriage of the polymorphic gene variants of clotting factors in adolescents in Barnaul. Siberian Medical Review. 2015;(3):53-6. (In Russ).

[38] Строзенко Л.А., Гордеев В.В., Лобанов Ю.Ф., и др. Частота носительства полиморфных вариантов генов фак-торов свертывания крови у подростков города Барнаул // Сибирское медицинское обозрение. 2015. №3. С. 53-56.

[39] Lobastov KV, Barinov VE, Schastlivtsev IV, et al. Sovremennye podkhody k diagnostike i terapii ostrogo venoznogo tromboza. Moscow: Triumf; 2016. (In Russ).

[40] Лобастов К.В., Баринов В.Е., Счастливцев И.В., и др. Современные подходы к диагностике и терапии острого венозного тромбоза. М.: Триумф; 2016.

[41] Pizova NV. Trombofilii: geneticheskie polimorfizmy i sosudistye katastrofy. Moscow: IMA-PRESS; 2013. (In Russ).

[42] Пизова Н.В. Тромбофилии: генетические полиморфизмы и сосудистые катастрофы. М.: ИМА-ПРЕСС; 2013.

RIGHTS & PERMISSIONS

Zykova T.A., Vladimirova L.Y., Katelnitskaya O.V., Maslov A.A., Shevyakova E.A., Lysenko I.B., Abramova N.A., Storozhakova A.E., Popova I.L., Novoselova K.A., Tikhanovskaya N.M., Lyanova A.A., Ryadinskaya L.A., Tishina A.V., Tishchenko I.S., Kabanov S.N., Kalabanova E.A.